http://www.earningsimpact.com/Trans...achs-34th-Annual-Global-Healthcare-Conference
"So every two months dosing. Whereas if you look all the trials that have been, being done since then that has compared monthly Lucentis or monthly Avastin for that matter to less frequent dosing regimens this PRN dosing regimen, you typically see a decline in level of effect whereas when you compare RV1, V2 trials you see our every other months EYLEA compared to month of Lucentis usually clinically equivalent.
And however, one of the surprises for us was we developed this to be the frontline agent and the benefit of being less frequent dosing, it turns out that physicians use it primarily right out of the gate in the more difficult to treat patients. This disease what AMD is characterized by wax or fluid in the back of the eye the retina and unfortunately many patients who're on therapy despite even monthly therapy with the existing therapies continue to have fluid in the back of the retina and when physicians switch those patients to EYLEA the anecdotal responses were very positive. And since that time, since our launch has been multiple presentations by investigators showing case series of the patients, that the patients have the resolved."
"So every two months dosing. Whereas if you look all the trials that have been, being done since then that has compared monthly Lucentis or monthly Avastin for that matter to less frequent dosing regimens this PRN dosing regimen, you typically see a decline in level of effect whereas when you compare RV1, V2 trials you see our every other months EYLEA compared to month of Lucentis usually clinically equivalent.
And however, one of the surprises for us was we developed this to be the frontline agent and the benefit of being less frequent dosing, it turns out that physicians use it primarily right out of the gate in the more difficult to treat patients. This disease what AMD is characterized by wax or fluid in the back of the eye the retina and unfortunately many patients who're on therapy despite even monthly therapy with the existing therapies continue to have fluid in the back of the retina and when physicians switch those patients to EYLEA the anecdotal responses were very positive. And since that time, since our launch has been multiple presentations by investigators showing case series of the patients, that the patients have the resolved."